ATT-Heart Trial

The trial uses three sequential cohorts of three patients in a single ascending dose design. Each patient receives one 10 mL intravenous dose of TR006 at the bedside after the product is thawed. TR006 is administered 3 to 6 months after transplant to avoid Basiliximab-mediated CD25 blockade and confirm absence of rejection.